My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 221

    1.

    Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection.

    Simó R, Lecube A, Genescà J, Esteban JI, Hernández C.

    Diabetes Care. 2006 Nov;29(11):2462-6.PMID: 17065685 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.

    Giordanino C, Bugianesi E, Smedile A, Ciancio A, Abate ML, Olivero A, Pellicano R, Cassader M, Gambino R, Bo S, Ciccone G, Rizzetto M, Saracco G.

    Am J Gastroenterol. 2008 Oct;103(10):2481-7. Epub 2008 Aug 8.PMID: 18702647 [PubMed - indexed for MEDLINE]Related articles

    3.

    Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.

    Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Ikeda K, Kumada H.

    Hepatology. 2009 Mar;49(3):739-44.PMID: 19127513 [PubMed - indexed for MEDLINE]Related articles

    4.

    Glucose abnormalities are an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

    Lecube A, Hernández C, Simó R, Esteban JI, Genescà J.

    Am J Gastroenterol. 2007 Oct;102(10):2189-95. Epub 2007 Jul 7.PMID: 17617205 [PubMed - indexed for MEDLINE]Related articles

    5.

    Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study.

    Benetti G, Borzio M, Ramella G, Bellati G, Fargion S, Colombo A, Croce G, Iamoletti C, Balzola F, Rizzetto M; GEL (Gruppo Epatologico Lombardo).

    Intern Emerg Med. 2006;1(2):113-8.PMID: 17111783 [PubMed - indexed for MEDLINE]Related articles

    6.

    Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis.

    Castéra L, Hézode C, Roudot-Thoraval F, Lonjon I, Zafrani ES, Pawlotsky JM, Dhumeaux D.

    Gut. 2004 Mar;53(3):420-4.PMID: 14960527 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Risk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infection.

    Chehadeh W, Abdella N, Ben-Nakhi A, Al-Arouj M, Al-Nakib W.

    J Gastroenterol Hepatol. 2009 Jan;24(1):42-8. Epub 2008 Aug 20.PMID: 18717762 [PubMed - indexed for MEDLINE]Related articles

    8.

    Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.

    Chehadeh W, Al-Nakib W.

    J Med Virol. 2009 Apr;81(4):610-8.PMID: 19235842 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C.

    Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ, Diago M, Alonso S, Planas R, Solá R, Pons JA, Salmerón J, Barcena R, Perez R, Carmona I, Durán S.

    J Hepatol. 2008 May;48(5):721-7. Epub 2008 Jan 15.PMID: 18308416 [PubMed - indexed for MEDLINE]Related articles

    10.

    Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

    Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

    Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210. PMID: 18081356 [PubMed - indexed for MEDLINE]Related articles

    11.

    A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.

    Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, Sheen IS, Chang WY, Lee CM, Liaw YF.

    Antivir Ther. 2006;11(8):985-94.PMID: 17302368 [PubMed - indexed for MEDLINE]Related articles

    12.

    Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.

    Dore GJ, Torriani FJ, Rodriguez-Torres M, Bräu N, Sulkowski M, Lamoglia RS, Tural C, Clumeck N, Nelson MR, Mendes-Correa MC, Godofsky EW, Dieterich DT, Yetzer E, Lissen E, Cooper DA.

    AIDS. 2007 Jul 31;21(12):1555-9.PMID: 17630550 [PubMed - indexed for MEDLINE]Related articles

    13.

    Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.

    Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN.

    J Gastroenterol Hepatol. 2007 May;22(5):669-75.PMID: 17444854 [PubMed - indexed for MEDLINE]Related articles

    14.

    High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study.

    Yu ML, Dai CY, Chen SC, Lee LP, Hsieh MY, Lin ZY, Hsieh MY, Wang LY, Tsai JF, Chang WY, Chuang WL.

    BMC Infect Dis. 2005 Apr 12;5(1):27.PMID: 15823212 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Association of diabetes mellitus and chronic hepatitis C virus infection.

    Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, Everhart JE, Wasserfall C, Maclaren NK, Perrillo RP.

    Hepatology. 1999 Feb;29(2):328-33.PMID: 9918906 [PubMed - indexed for MEDLINE]Related articles

    16.

    [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics]

    Husa P, Slesinger P, Stroblová H, Svobodník A, Husová L.

    Klin Mikrobiol Infekc Lek. 2008 Apr;14(2):67-73. Czech. PMID: 18756436 [PubMed - indexed for MEDLINE]Related articles

    17.

    Interferon beta 1a versus interferon beta 1a plus ribavirin for the treatment of chronic hepatitis C in Chinese patients: a randomized, placebo-controlled trial.

    Han Q, Liu Z, Kang W, Li H, Zhang L, Zhang N.

    Dig Dis Sci. 2008 Aug;53(8):2238-45. Epub 2007 Dec 13.PMID: 18080763 [PubMed - indexed for MEDLINE]Related articles

    18.

    Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.

    Yu JW, Wang GQ, Sun LJ, Li XG, Li SC.

    J Gastroenterol Hepatol. 2007 Jun;22(6):832-6.PMID: 17565637 [PubMed - indexed for MEDLINE]Related articles

    19.

    Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.

    Crespo M, Sauleda S, Esteban JI, Juarez A, Ribera E, Andreu AL, Falco V, Quer J, Ocaña I, Ruiz I, Buti M, Pahissa A, Esteban R, Guardia J.

    J Viral Hepat. 2007 Apr;14(4):228-38.PMID: 17381714 [PubMed - indexed for MEDLINE]Related articles

    20.

    Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.

    Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.

    AIDS. 2008 Jan 2;22(1):15-21.PMID: 18090387 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity